US lawmakers seek briefing on plans to export vaccines to other countries

A group of American lawmakers has sought from the Biden Administration a briefing on how they plan to provide Covid-19 vaccines to India and other countries experiencing a surge in coronavirus cases

Topics
Coronavirus | Coronavirus Vaccine | AstraZeneca

Press Trust of India  |  Washington 

Photo: Shutterstock
Photo: Shutterstock

A group of American lawmakers on Monday sought from the Biden Administration a briefing on how they plan to provide COVID-19 vaccines to India and other countries experiencing a surge in coronvairus cases.

In a letter to Secretary of State Tony Blinken and Secretary of Health and Human Services Xavier Becerra, the four lawmakers praised the decision to distribute among several nations 60 million vaccines, which cannot be used in the US.

The letter was written by Indian-American Congressman Raja Krishnamoorthi, Chair of the Oversight Subcommittee on Economic and Consumer Policy; Oversight Committee Chairwoman Carolyn Maloney, Select Subcommittee on the Crisis Chairman James Clyburn and Subcommittee on National Security Chairman Stephen.

Expressing concern over potential delays in shipping the first round of vaccines to India and other nations due to an additional FDA review, they sought a briefing from the Biden Administration on the process and how many doses the countries will receive.

They also sought a briefing on the timeline for shipping doses to other countries, whether the United States expects to have enough supply of vaccines from other manufacturers to inoculate the American public without the use of the vaccine; and whether any legal or contractual barriers present obstacles to shipping doses abroad.

Countries such as India, Argentina and Brazil are facing massive surges in infections. In India alone, more than one million new cases of COVID-19 were detected in just three days. The administration's decision also makes sense because the AstraZeneca vaccine cannot currently be used in America as the company has not yet applied for Emergency Use Authorisation from the Food and Drug Administration, the letter said.

Referring to recent remarks of White House Press Secretary Jen Psaki that these shipments will not happen right away and that no doses will be shared until the Food and Drug Administration has concluded its review, which may take several more weeks, the lawmakers said time is of the essence.

Without assistance from the United States, new vaccine-resistant mutations could arise across the globe, threatening international public health and the United States' national security and economic prosperity, the lawmakers said in the letter.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus
First Published: Tue, May 04 2021. 06:40 IST
RECOMMENDED FOR YOU